On a map of global climate tech, Zanzibar is not a typical pin. It is an archipelago known for spice farms and fishing dhows, not biopolymer labs. But for Lavine Irvine, a data scientist who has worked at GSK and BMW, it is the only place that made sense for Coastal Biotech. Her startup is trying to turn the island’s abundant seaweed into a suite of agricultural products, from organic biostimulants to crop protectants, and sell them back to local farmers and global manufacturers.
A fully integrated bet on macroalgae
Coastal Biotech is attempting to do it all, from R&D to contract manufacturing, under one roof in Zanzibar. The company’s public positioning describes it as a “fully integrated manufacturer” of premium agricultural products derived from marine plants. Its planned product slate is broad, organized into three buckets:
- Biostimulants and crop protectants: Organic, seaweed-based alternatives to synthetic fertilizers and pesticides.
- Food and feed ingredients: Processed macroalgae as a functional ingredient for human food and animal feed.
- Bio-materials: Developing biopolymers and other algae-based materials for industrial applications.
Why Zanzibar, and why now?
The bet hinges on a local resource. Zanzibar already has an established seaweed farming sector. Coastal Biotech aims to move up the value chain from that commodity base. By sourcing locally, the company avoids import costs and can build a narrative of community economic development alongside carbon-negative operations. The team, while small, is built for this dual challenge of deep tech and local operations. CEO Lavine Irvine brings an analytical, operational background from multinational corporations [NextCapital, retrieved 2026]. Danford Mkunda, focused on R&D, adds a biochemical specialization in biopolymers and higher-value compounds [Munich Startup, retrieved 2026].
The risks of a three-front war
Coastal Biotech’s integrated model is a high-wire act for a pre-seed company. The public record shows participation in the SAIS Accelerator but no disclosed equity funding rounds [SAIS Accelerator, retrieved 2026]. Building a biomanufacturing facility is capital-intensive. While the company claims its operations are carbon-negative, specific, verifiable data on lifecycle emissions or long-term offtake agreements with buyers are not yet public.
What to watch in the next 18 months
The company’s near-term milestones are physical and financial. The construction and commissioning of its planned seaweed fertilizer factory will be the first major proof point of its integrated model. Following that, the first announced commercial contract would validate demand beyond the local farm gate. Finally, a priced equity round would signal investor belief in the capital plan.